Ascendis announces 2-year results from post-hoc analysis of Phase 3 trial

Ascendis Pharma announced 2-year results from a post-hoc analysis of the Company’s Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function in adults with chronic hypoparathyroidism treated with TransCon PTH. The data were shared in an oral presentation on May 12 by Peter Schwarz, M.D., Professor of Clinical Medicine at the University of Copenhagen, during the European Congress of Endocrinology 2024, the annual meeting of the European Society of Endocrinology. The post-hoc analysis examined the impact of treatment with TransCon PTH on renal function using estimated glomerular filtration rate through Week 104 of PaTHway, a Phase 3 double-blind, placebo-controlled trial of 82 dosed adults with chronic hypoparathyroidism randomized 3:1, with a 26-week blinded period followed by an ongoing 156-week open-label extension period. Across both treatment arms, TransCon PTH treatment resulted in a mean eGFR increase of 8.9 mL/min/1.73m2 from baseline at Week 52, sustained at Week 104 with a mean change from baseline of 9.0 mL/min/1.73m2. Treatment was generally well-tolerated, with no new safety signals